MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
1.710
-0.150
-8.06%
After Hours: 1.661 -0.049 -2.89% 19:31 12/05 EST
OPEN
1.850
PREV CLOSE
1.860
HIGH
1.930
LOW
1.691
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
26.05
52 WEEK LOW
1.390
MARKET CAP
47.85M
P/E (TTM)
-0.2897
1D
5D
1M
3M
1Y
5Y
1D
3 Penny Stocks to Watch Now, 12/4/25
TipRanks · 2d ago
RBC Capital Sticks to Its Hold Rating for Jasper Therapeutics (JSPR)
TipRanks · 4d ago
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
TipRanks · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR)
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR)
TipRanks · 4d ago
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
TipRanks · 4d ago
Jasper Stock Jumps After Promising New Asthma Study Results
Benzinga · 4d ago
Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study
NASDAQ · 5d ago
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.